Recent secondary market transactions have marked Neuralink at $42 billion to nearly $60 billion as of October 2026, reflecting a sharp increase from the $9–10 billion post-money valuation of its June 2025 Series E round. This surge stems from demonstrated advances in brain-computer interface performance, including a new 11.32 bits-per-second cursor control record and a foundation model trained on over 50,000 hours of participant data that reduced daily calibration needs. With 21-plus human trial participants and ongoing preclinical work, trader sentiment on near-term valuation thresholds incorporates both the company’s capital-light structure and sustained institutional demand for high-growth neurotechnology assets ahead of the December 31 resolution.